‘Third Sector’ Drug Sales Will Grow To $14 Billion In U.S. In 2018 – IMS
This article was originally published in The Pink Sheet Daily
Executive Summary
Products based on older ingredients but offering new routes of administration, new formulations or new indications should continue to see solid growth, IMS white paper says; leading players in the space include both brand and generic firms.